Accuracy of point‐of‐care HbA1c testing in pregnant women

Culliney, Katherine AT; McCowan, Lesley; Okesene-Gafa, Karaponi; Murphy, Rinki; Rowan, Janet; Taylor, Rennae S.; McKinlay, Christopher J.D.

doi:10.1111/ajo.12786

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gestational weight gain (GWG) was defined as mean weekly weight gain between recruitment to 28 and 36 weeks' gestation by Institute of Medicine criteria [18]. Finger-prick non-fasting blood lipid and HbA 1c testing was conducted at each study visit (recruitment,) using the Roche Cobas b 101 point-of-care system [19]. A non-fasting blood (buffy coat) specimen was collected for genetic testing in consenting women.…”

Section: Methodsmentioning

confidence: 99%

The Pacific-specific CREBRF rs373863828 allele protects against gestational diabetes mellitus in Māori and Pacific women with obesity

et al. 2020

Self Cite

View full text Add to dashboard Cite

Aims/hypothesis The CREBRF rs373863828 minor (A) allele is associated with increased BMI but reduced prevalence of type 2 diabetes in Māori and Pacific people. Given the shared aetiology of type 2 diabetes and gestational diabetes mellitus (GDM), we tested for an association between the CREBRF rs373863828 variant and GDM. Methods We conducted a prospective cohort study of Māori and Pacific women nested within a nutritional intervention study for pregnant women with obesity. Women were enrolled at 12-17 weeks' gestation and underwent anthropometry and collection of buffy coats for later genetic testing. GDM was diagnosed by 75 g OGTT at 24-28 weeks' gestation using the International Association of Diabetes and Pregnancy Study Groups criteria. Genotyping was performed by real-time PCR with a custom CREBRF rs373863828 probe-set. The association between CREBRF rs373863828 and GDM was analysed separately by ethnic group using logistic regression, with effect estimates combined in a meta-analysis. Results Of 112 Māori and Pacific pregnant women with obesity, 31 (28%) carried the CREBRF rs373863828 A allele (A/G or A/A) and 35 (31%) developed GDM. Women who carried the CREBRF rs373863828 A allele did not differ in BMI when compared with non-carriers (G/G). There was a fivefold reduction in the likelihood of GDM per CREBRF rs373863828 A allele (OR 0.19 [95% CI 0.05, 0.69], p = 0.01), independent of age, BMI and family history of diabetes (adjusted OR 0.13 [95% CI 0.03, 0.53], p = 0.004). GDM was diagnosed in 10% and 40% of women with and without the CREBRF rs373863828 A allele, respectively (no woman with the A/A genotype developed GDM). Conclusions/interpretation The CREBRF rs373863828 (A) allele is associated with reduced likelihood of GDM in Māori and Pacific women with obesity and may improve GDM risk prediction.

show abstract

Section: Methodsmentioning

confidence: 99%